StreetInsider.com News Articles http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 04 Aug 2026 21:03:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Form 4 Inhibitor Therapeutics, For: Jul 01 Filed by: MCNULTY JAMES A http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+Jul+01++Filed+by%3A+MCNULTY+JAMES+A/26868636.html si-local-file:///var/storage/secattach/20260804/26868636.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+Jul+01++Filed+by%3A+MCNULTY+JAMES+A/26868636.html Tue, 04 Aug 2026 21:03:00 -0400 INTI O.15980976 Form 4 Inhibitor Therapeutics, For: Jul 01 Filed by: MCNULTY JAMES A http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+Jul+01++Filed+by%3A+MCNULTY+JAMES+A/26868636.html si-local-file:///var/storage/secattach/20260804/26868636.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+Jul+01++Filed+by%3A+MCNULTY+JAMES+A/26868636.html Tue, 04 Aug 2026 21:03:00 -0400 INTI O.15980976 Form 4 Inhibitor Therapeutics, For: May 04 Filed by: OSMAN RONALD E http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+04++Filed+by%3A+OSMAN+RONALD+E/26864743.html si-local-file:///var/storage/secattach/20260804/26864743.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+04++Filed+by%3A+OSMAN+RONALD+E/26864743.html Tue, 04 Aug 2026 13:33:00 -0400 INTI O.15980976 Form 4 Inhibitor Therapeutics, For: May 04 Filed by: OSMAN RONALD E http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+04++Filed+by%3A+OSMAN+RONALD+E/26864743.html si-local-file:///var/storage/secattach/20260804/26864743.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+04++Filed+by%3A+OSMAN+RONALD+E/26864743.html Tue, 04 Aug 2026 13:33:00 -0400 INTI O.15980976 Form 4 Inhibitor Therapeutics, For: May 04 Filed by: Yanez Michelle http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+04++Filed+by%3A+Yanez+Michelle/26864383.html si-local-file:///var/storage/secattach/20260804/26864383.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+04++Filed+by%3A+Yanez+Michelle/26864383.html Tue, 04 Aug 2026 12:19:00 -0400 INTI O.15980976 Form 4 Inhibitor Therapeutics, For: May 04 Filed by: Yanez Michelle http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+04++Filed+by%3A+Yanez+Michelle/26864383.html si-local-file:///var/storage/secattach/20260804/26864383.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+04++Filed+by%3A+Yanez+Michelle/26864383.html Tue, 04 Aug 2026 12:19:00 -0400 INTI O.15980976 Form 4 Inhibitor Therapeutics, For: May 04 Filed by: SEARS SAMUEL P JR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+04++Filed+by%3A+SEARS+SAMUEL+P+JR/26864367.html si-local-file:///var/storage/secattach/20260804/26864367.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+04++Filed+by%3A+SEARS+SAMUEL+P+JR/26864367.html Tue, 04 Aug 2026 12:15:00 -0400 INTI O.15980976 Form 4 Inhibitor Therapeutics, For: May 04 Filed by: SEARS SAMUEL P JR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+04++Filed+by%3A+SEARS+SAMUEL+P+JR/26864367.html si-local-file:///var/storage/secattach/20260804/26864367.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+04++Filed+by%3A+SEARS+SAMUEL+P+JR/26864367.html Tue, 04 Aug 2026 12:15:00 -0400 INTI O.15980976 Form 4 Inhibitor Therapeutics, For: May 04 Filed by: ODONNELL FRANCIS E JR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+04++Filed+by%3A+ODONNELL+FRANCIS+E+JR/26864212.html si-local-file:///var/storage/secattach/20260804/26864212.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+04++Filed+by%3A+ODONNELL+FRANCIS+E+JR/26864212.html Tue, 04 Aug 2026 11:56:00 -0400 INTI O.15980976 Form 4 Inhibitor Therapeutics, For: May 04 Filed by: ODONNELL FRANCIS E JR http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+04++Filed+by%3A+ODONNELL+FRANCIS+E+JR/26864212.html si-local-file:///var/storage/secattach/20260804/26864212.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+04++Filed+by%3A+ODONNELL+FRANCIS+E+JR/26864212.html Tue, 04 Aug 2026 11:56:00 -0400 INTI O.15980976 Form 4 Inhibitor Therapeutics, For: May 04 Filed by: Jerman Michael Allen http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+04++Filed+by%3A+Jerman+Michael+Allen/26684570.html si-local-file:///var/storage/secattach/20260624/26684570.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+04++Filed+by%3A+Jerman+Michael+Allen/26684570.html Wed, 24 Jun 2026 12:35:00 -0400 INTI O.15980976 Form 4 Inhibitor Therapeutics, For: May 04 Filed by: Jerman Michael Allen http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+04++Filed+by%3A+Jerman+Michael+Allen/26684570.html si-local-file:///var/storage/secattach/20260624/26684570.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+04++Filed+by%3A+Jerman+Michael+Allen/26684570.html Wed, 24 Jun 2026 12:35:00 -0400 INTI O.15980976 Form 4 Inhibitor Therapeutics, For: May 05 Filed by: Vasisht Niraj http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+05++Filed+by%3A+Vasisht+Niraj/26583853.html si-local-file:///var/storage/secattach/20260601/26583853.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+05++Filed+by%3A+Vasisht+Niraj/26583853.html Mon, 01 Jun 2026 16:16:00 -0400 INTI O.15980976 Form 4 Inhibitor Therapeutics, For: May 05 Filed by: Vasisht Niraj http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+05++Filed+by%3A+Vasisht+Niraj/26583853.html si-local-file:///var/storage/secattach/20260601/26583853.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibitor+Therapeutics%2C+++For%3A+May+05++Filed+by%3A+Vasisht+Niraj/26583853.html Mon, 01 Jun 2026 16:16:00 -0400 INTI O.15980976 Form 10-Q Inhibitor Therapeutics, For: Mar 31 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Inhibitor+Therapeutics%2C+++For%3A+Mar+31/26504060.html si-local-file:///var/storage/secattach/20260515/26504060.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Inhibitor+Therapeutics%2C+++For%3A+Mar+31/26504060.html Fri, 15 May 2026 15:01:00 -0400 INTI O.15980976 Form 10-Q Inhibitor Therapeutics, For: Mar 31 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Inhibitor+Therapeutics%2C+++For%3A+Mar+31/26504060.html si-local-file:///var/storage/secattach/20260515/26504060.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Inhibitor+Therapeutics%2C+++For%3A+Mar+31/26504060.html Fri, 15 May 2026 15:01:00 -0400 INTI O.15980976 Form 8-K Inhibitor Therapeutics, For: Apr 01 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibitor+Therapeutics%2C+++For%3A+Apr+01/26259072.html si-local-file:///var/storage/secattach/20260401/26259072.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibitor+Therapeutics%2C+++For%3A+Apr+01/26259072.html Wed, 01 Apr 2026 16:06:00 -0400 INTI O.15980976 Form 8-K Inhibitor Therapeutics, For: Apr 01 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibitor+Therapeutics%2C+++For%3A+Apr+01/26259072.html si-local-file:///var/storage/secattach/20260401/26259072.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibitor+Therapeutics%2C+++For%3A+Apr+01/26259072.html Wed, 01 Apr 2026 16:06:00 -0400 INTI O.15980976 Form 8-K Inhibitor Therapeutics, For: Apr 01 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibitor+Therapeutics%2C+++For%3A+Apr+01/26255184.html si-local-file:///var/storage/secattach/20260401/26255184.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibitor+Therapeutics%2C+++For%3A+Apr+01/26255184.html Wed, 01 Apr 2026 08:01:00 -0400 INTI O.15980976 Form 8-K Inhibitor Therapeutics, For: Apr 01 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibitor+Therapeutics%2C+++For%3A+Apr+01/26255184.html si-local-file:///var/storage/secattach/20260401/26255184.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibitor+Therapeutics%2C+++For%3A+Apr+01/26255184.html Wed, 01 Apr 2026 08:01:00 -0400 INTI O.15980976 Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome http://www.streetinsider.com/Press+Releases/Inhibitor+Therapeutics+Provides+Clinical%2C+Formulation+and+IP+Update+on+Itraconazole+Program+for+Gorlin+Syndrome/26250359.html <p align="justify">TAMPA, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. (OTCQB: INTI) (&quot;Inhibitor&quot; or the &quot;Company&quot;), today provided an update on its ongoing pharmacokinetic (PK) clinical program supporting the treatment of surgically eligible basal cell carcinomas (BCCs) in Basal Cell Carcinoma Nevus Syndrome (BCCNS), also known as Gorlin Syndrome, and announced plans to file a new global patent application covering its proprietary itraconazole formulation.</p> <p align="justify">Inhibitor&apos;s comparative PK, safety and tolerability study is being conducted in healthy adult subjects under fasting conditions in Malaysia and is designed as a three-way crossover study against a reference http://www.streetinsider.com/Press+Releases/Inhibitor+Therapeutics+Provides+Clinical%2C+Formulation+and+IP+Update+on+Itraconazole+Program+for+Gorlin+Syndrome/26250359.html Tue, 31 Mar 2026 15:44:00 -0400 A.06822034 INTI O.15980976 O.20026344 Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome http://www.streetinsider.com/Press+Releases/Inhibitor+Therapeutics+Provides+Clinical%2C+Formulation+and+IP+Update+on+Itraconazole+Program+for+Gorlin+Syndrome/26250359.html <p align="justify">TAMPA, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. (OTCQB: INTI) (&quot;Inhibitor&quot; or the &quot;Company&quot;), today provided an update on its ongoing pharmacokinetic (PK) clinical program supporting the treatment of surgically eligible basal cell carcinomas (BCCs) in Basal Cell Carcinoma Nevus Syndrome (BCCNS), also known as Gorlin Syndrome, and announced plans to file a new global patent application covering its proprietary itraconazole formulation.</p> <p align="justify">Inhibitor&apos;s comparative PK, safety and tolerability study is being conducted in healthy adult subjects under fasting conditions in Malaysia and is designed as a three-way crossover study against a reference http://www.streetinsider.com/Press+Releases/Inhibitor+Therapeutics+Provides+Clinical%2C+Formulation+and+IP+Update+on+Itraconazole+Program+for+Gorlin+Syndrome/26250359.html Tue, 31 Mar 2026 15:44:00 -0400 A.06822034 INTI O.15980976 O.20026344 Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome http://www.streetinsider.com/Press+Releases/Inhibitor+Therapeutics+Provides+Clinical%2C+Formulation+and+IP+Update+on+Itraconazole+Program+for+Gorlin+Syndrome/26250359.html <p align="justify">TAMPA, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. (OTCQB: INTI) (&quot;Inhibitor&quot; or the &quot;Company&quot;), today provided an update on its ongoing pharmacokinetic (PK) clinical program supporting the treatment of surgically eligible basal cell carcinomas (BCCs) in Basal Cell Carcinoma Nevus Syndrome (BCCNS), also known as Gorlin Syndrome, and announced plans to file a new global patent application covering its proprietary itraconazole formulation.</p> <p align="justify">Inhibitor&apos;s comparative PK, safety and tolerability study is being conducted in healthy adult subjects under fasting conditions in Malaysia and is designed as a three-way crossover study against a reference http://www.streetinsider.com/Press+Releases/Inhibitor+Therapeutics+Provides+Clinical%2C+Formulation+and+IP+Update+on+Itraconazole+Program+for+Gorlin+Syndrome/26250359.html Tue, 31 Mar 2026 15:44:00 -0400 A.06822034 INTI O.15980976 O.20026344 Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome http://www.streetinsider.com/Press+Releases/Inhibitor+Therapeutics+Provides+Clinical%2C+Formulation+and+IP+Update+on+Itraconazole+Program+for+Gorlin+Syndrome/26250359.html <p align="justify">TAMPA, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. (OTCQB: INTI) (&quot;Inhibitor&quot; or the &quot;Company&quot;), today provided an update on its ongoing pharmacokinetic (PK) clinical program supporting the treatment of surgically eligible basal cell carcinomas (BCCs) in Basal Cell Carcinoma Nevus Syndrome (BCCNS), also known as Gorlin Syndrome, and announced plans to file a new global patent application covering its proprietary itraconazole formulation.</p> <p align="justify">Inhibitor&apos;s comparative PK, safety and tolerability study is being conducted in healthy adult subjects under fasting conditions in Malaysia and is designed as a three-way crossover study against a reference http://www.streetinsider.com/Press+Releases/Inhibitor+Therapeutics+Provides+Clinical%2C+Formulation+and+IP+Update+on+Itraconazole+Program+for+Gorlin+Syndrome/26250359.html Tue, 31 Mar 2026 15:44:00 -0400 A.06822034 INTI O.15980976 O.20026344 Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome http://www.streetinsider.com/Globe+Newswire/Inhibitor+Therapeutics+Provides+Clinical%2C+Formulation+and+IP+Update+on+Itraconazole+Program+for+Gorlin+Syndrome/26250359.html <p align="justify">TAMPA, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- Inhibitor Therapeutics, Inc. (OTCQB: INTI) (&quot;Inhibitor&quot; or the &quot;Company&quot;), today provided an update on its ongoing pharmacokinetic (PK) clinical program supporting the treatment of surgically eligible basal cell carcinomas (BCCs) in Basal Cell Carcinoma Nevus Syndrome (BCCNS), also known as Gorlin Syndrome, and announced plans to file a new global patent application covering its proprietary itraconazole formulation.</p> <p align="justify">Inhibitor&apos;s comparative PK, safety and tolerability study is being conducted in healthy adult subjects under fasting conditions in Malaysia and is designed as a three-way crossover study against a reference http://www.streetinsider.com/Globe+Newswire/Inhibitor+Therapeutics+Provides+Clinical%2C+Formulation+and+IP+Update+on+Itraconazole+Program+for+Gorlin+Syndrome/26250359.html Tue, 31 Mar 2026 15:44:00 -0400 A.06822034 INTI O.15980976 O.20026344